Clinical Trial: Study Evaluating MYO-029 in Adult Muscular Dystrophy
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title:
Brief Summary: The purpose of this phase I/II, multicenter, safety trial is to study MYO-029 in adult patients with muscular dystrophy.
Detailed Summary:
Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
Current Primary Outcome: Safety assessment
Original Primary Outcome:
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Wyeth is now a wholly owned subsidiary of Pfizer
Dates:
Date Received: February 22, 2005
Date Started: February 2005
Date Completion:
Last Updated: December 19, 2007
Last Verified: December 2007